Mirati Therapeutics was created from the drug discovery foundation of MethylGene and reshaped under the direction of a new leadership team with extensive experience in successful development and registration of targeted oncology drugs.

This USA-based company's pipeline includes Krazati (adagrasib), a targeted treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) that won US regulatory accelerated approval in December 2022.